Review Article

Prostasin: An Epithelial Sodium Channel Regulator

Shakti Aggarwal,¹ Pradeep K. Dabla,² and Sarika Arora¹

¹ Department of Biochemistry, ESI Hospital, Basai Darapur, New Delhi 110015, India

² Department of Biochemistry, Chacha Nehru Bal Chikitsalaya, New Delhi 110031, India

Correspondence should be addressed to Sarika Arora; sarikaarora08@rediffmail.com

Received 31 January 2013; Revised 3 June 2013; Accepted 4 June 2013

Academic Editor: José Luis Martín-Ventura

Copyright © 2013 Shakti Aggarwal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prostasin is a glycoposphatidylinositol-anchored protein which is found in prostate gland, kidney, bronchi, colon, liver, lung, pancreas, and salivary glands. It is a serine protease with trypsin-like substrate specificity which was first purified from seminal fluid in 1994. In the last decade, its diverse roles in various biological and physiological processes have been elucidated. Many studies done to date suggest that prostasin is one of several membrane peptidases regulating epithelial sodium channels in mammals. A comprehensive literature search was conducted from the websites of Pubmed Central, the US National Library of Medicine's digital archive of life sciences literature and the National Library of Medicine. The data was also assessed from journals and books that published relevant articles in this field. Understanding the mechanism by which prostasin and its inhibitors regulate sodium channels has provided a new insight into the treatment of hypertension and some other diseases like cystic fibrosis. Prostasin plays an important role in epidermal growth factor receptor (EGFR) signal modulation. Extracellular proteases have been implicated in tumor metastasis and local tissue invasion because of their ability to degrade extracellular matrices.

1. Introduction

Prostasin (also known as channel activating protease 1) is a novel extracellular serine protease with trypsin-like activity which cleaves synthetic substrates *in vitro*, preferentially at carboxy-terminal side of arginine residue. The serine proteases constitute one of the largest classes of proteolytic enzymes and have evolved to perform specialized functions. The catalytic triad that is essential for the enzymatic activity of prostasin is a histidine, aspartic acid, and serine sequence. Prostasin belongs to the classical serine protease family, with homology to trypsin, chymotrypsin, and kallikrein, and has a trypsin-like substrate specificity [1–3]. Trypsin-like serine proteases typically are synthesized as inactive zymogens that are activated by a single endoproteolytic cleavage. This group of enzymes often acts in either single or complex, highly regulated zymogen cascades to control important biological processes, such as coagulation, fibrinolysis, blood pressure, and digestion. The enzyme activation of prostasin occurs via cleavage of the proprotein to produce a light chain and a heavy chain that are disulfide linked [3]. Prostasin belongs to a distinct family of genes in syntenic regions of human chromosome 16p13.3/11.2 and mouse chromosomes

7 and 17 that includes tryptase- γ (TPSG), tryptase- ϵ , pancreatin, testisin, and distal intestinal serine protease [4]. In addition to being secreted, prostasin is expressed as a glycosylphosphatidylinositol- (GPI-) anchored membrane protein in prostate epithelial cells [5]. Soluble prostasin, purified from human seminal fluid, terminates at Arg323, suggesting that prostasin may be secreted via tryptic cleavage of its COOH terminal hydrophobic domain [1].

Prostasin was first identified as a product secreted by prostate gland and hence the name. Later on, techniques like immunolocalization, mRNA blotting, and *in situ* hybridization studies demonstrated that it was present in various other tissues like kidneys, lungs and airway, liver, pancreas, and salivary glands [2, 6, 7]. When characterization of cDNA allowed the prediction of the full precursor sequence, prostasin was recognized to be synthesized initially as a transmembrane protein with a C-terminal peptide anchor [2]. The C-terminal anchor is the defining characteristic of the type I transmembrane serine peptidases, a subset of vertebrate, trypsin-family peptidases [8, 9].

Prostasin is expressed mainly in mammalian epithelial tissues of prostate, kidney, lung, and colon as a 40 kDa glycosylphosphatidylinositol- (GPI-) anchored protein [1–3].

Although the biological and physiological roles of prostaticin are not known at present, the high levels of prostaticin in the prostate and seminal fluid (over 20-fold higher than any other tissue examined) suggest that it may play an important physiological role in these locations [10]. As evidenced from various studies, prostaticin is present at low levels in other tissues, such as the lung, kidney, salivary glands, colon, liver, and bronchi, indicating that it may have roles in other biological processes as well [1]. In normal ovarian tissue, prostaticin is not highly expressed [2, 11].

A physiological function defined for prostaticin is the proteolytic activation of the epithelial sodium channel (ENaC), an important regulator of sodium balance [7, 12, 13]. It is suggested that the full activation of ENaC is accomplished via a proteolytic cleavage of the ENaC gamma subunit by furin and a second cleavage presumably by prostaticin [14]. Prostaticin also plays important roles in maintaining the epidermal permeability barrier [15], regulating the inducible nitric oxide synthase gene expression during lipopolysaccharide-induced bladder inflammation [16], and regulating transepithelial resistance and current [4]. Prostaticin has some additional features that are unusual in serine proteases, such as a high degree of sensitivity to monovalent and divalent cations, which may relate to the prostaticin role in ENaC regulation [3].

Prostate cells can secrete and shed a fraction of prostaticins as soluble enzymes with the rest remaining attached by a glycosylphosphatidylinositol (GPI) anchor [5]. However, the precise mechanism by which prostaticin is secreted from cells has not been elucidated yet. Significantly, prostaticin shares several similarities with a membrane-anchored frog protein, *channel-activating protease*, identified by expression cloning as a regulator of Na⁺ transport in *Xenopus* kidney cells [12, 13]. In a *Xenopus* oocyte expression of full length, but not COOH-terminally truncated, soluble prostaticin/(CAP-1) results in activation of ENaC [13]. However, other investigators found that soluble, active prostaticin can augment ENaC activity in M-1 kidney cortical collecting duct cells [17]. Additionally, in vitro invasion studies showed that overexpression of wild-type prostaticin, but not a truncated secreted form of prostaticin, inhibits cell invasion [18, 19]. These observations suggest that prostaticin function may be regulated by membrane localization or secretion. However, the specific roles of the GPI anchor and COOH terminal domain have not been studied.

2. Structure of Prostaticin

The crystal structure of the protease domain of prostaticin is structurally similar to other serine proteases, consisting of two barrel-like subdomains with four conserved disulfide bonds. The two subdomains are separated by a cleft that contains the active site. In prostaticin, the catalytic triad is formed by His-85, Asp-134, and Ser-238, corresponding to chymotrypsin residues His-57, Asp-102, and Ser-195. The proximity of the hydroxyl group of Ser-238 to the imidazole ring of His-85 and the hydrogen bond between O of Asp-134 and N of His-85 suggest that the catalytic mechanism

observed in other serine proteases is conserved in prostaticin [20].

In comparison with other serine proteases with known structures, the core of the domain is highly conserved, whereas the loops are less conserved. The sequence identity between the protease domain of prostaticin and that of chymotrypsin, trypsin, elastase, and kallikrein is 37, 38, 32, and 39%, respectively [20]. Adjacent to the catalytic triad in serine proteases, there is a pocket that binds and confers specificity for the P1 position of substrates. In the structure of the prostaticin apoprotein, this pocket is occluded by a loop containing residues 258–262 [20]. For chymotrypsin-like serine proteases, the specificity for the P1 position of the substrate is primarily determined by a residue at the bottom of the S1 pocket (analogous to Ser-189 in chymotrypsin). In prostaticin, the equivalent residue is Asp-232, which is conserved in proteases characteristic of the trypsin family. This aspartate confers specificity toward lysine and arginine in the P1 position of substrates. In the structure of the 4-guanidinobenzoate ester adduct of prostaticin, the terminal guanidinium group of the inhibitor forms hydrogen bonds with both carboxylate oxygens of Asp-232. Additional hydrogen bonds to the inhibitor are provided by the carbonyl oxygens of Ala-233, Asp-260, and Arg-267 [20].

Shipway et al. [3] have extensively characterized prostaticin substrate specificity. They have found that prostaticin prefers an arginine or a lysine in the P1 position. The structure of the acyl-enzyme intermediate suggests that an arginine may be preferred over a lysine in the P1 position. The same group of researchers also found that metal ions regulate prostaticin activity, and divalent cations show more potent inhibition. One of the proposed mechanisms for divalent cation-mediated regulation may be to affect the energetic favourability for the loop conformation in which the loop moves to block or expose the S1 pocket [20].

3. Inhibitors of Prostaticin

The purified form of the human prostaticin exhibiting serine protease activity can be inhibited by aprotinin, antipain, leupeptin, and benzamidin [1]. In the serpin-class serine protease inhibitors, protease nexin-1 (PN-1) [21, 22] also known as glia-derived nexin (GDN) or serpin E2 [23] is the cognate serpin for prostaticin, forming a covalent complex with the latter to achieve inhibition of its serine protease activity. In the human PN-1 reactive site, the Leu-Ile-Ala-Arg residues at the P4-P1 positions of this suicide inhibitor are the optimal substrate for prostaticin. A Kunitz-type reversible serine protease inhibitor, hepatocyte growth factor activator inhibitor 1 (HAI-1) is a physiologically relevant inhibitor of prostaticin [24, 25], whereas HAI-2 can inhibit the prostaticin protease domain in vitro [3]. The two isoforms of hepatocyte growth factor activator inhibitor 1 (HAI-1), probably originating from two mRNA splice variants of *HAI-1*, are *HAI-1A* and *HAI-1B* [24]. The synthetic serine protease inhibitor camostat mesilate and its active metabolite FOY-251 can inhibit prostaticin serine protease activity in vitro [26] and possibly in vivo as well [27]. The enzymatic activity of

prostasin is influenced by the levels of PN-1, HAI-1A, and HAI-1B and probably also by the expression levels of many yet undiscovered inhibitors. The relative physiological importance of PN-1, HAI-1A and HAI-1B as inhibitors of prostasin is at present unclear. It is possible that prostasin activity is regulated by the modulation of the ratio between HAI-1A and HAI-1B as it is not clear whether the two inhibitors have the same kinetic properties. HAI-1B differs from HAI-1A by a 16 amino acid insertion [28]. Prostasin is part of the matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation [29]. Matriptase is thought to be the first protease in the cascade due to its ability to autoactivate [30, 31] and because prostasin is activated by a matriptase-catalysed cleavage [29]. The downstream target for prostasin is unclear, but the matriptase-prostasin cascade eventually regulates the processing of the differentiation marker filaggrin [15, 32] and is essential for the establishment of epidermal integrity [15, 33].

At the time of its identification, the exact role of prostasin in mammalian physiology was not known, but various studies have been done all over the world which highlight its diverse roles in various biological and physiological processes.

4. Role of Prostasin in Airway Clearance

Several lines of evidence suggest that one or more serine-class peptidases in vertebrate epithelia upregulate transepithelial Na^+ current mediated by ENaC, which is essential for airway fluid clearance [34]. For example, aprotinin, which is a broad-spectrum inhibitor of serine peptidases, reduces transepithelial Na^+ transport in frog kidney cells [35, 36]. Aprotinin's target appears to be channel-activating protease. Similar studies in cultured mammalian airway cells show that amiloride-sensitive Na^+ current is reversibly inhibited by aprotinin or bikunin (an inhibitor of tryptic serine peptidases) and restored by trypsin [5, 21, 34].

The direct mechanism of protease-mediated ENaC activation is unclear, but features increased probability of channel opening [15, 21, 35]. Several membrane-associated serine peptidases in addition to prostasin are candidate physiological activators of ENaC in mammalian epithelia [15, 28, 37]. The physiological substrates of prostasin and the direct mechanism for ENaC activation by serine peptidases remain unknown. Patch clamp experiments suggest that prostasin increases open probability of ENaC, but there is no evidence that prostasin directly cleaves ENaC α -, β -, or γ -subunits [12]. Evidence implicating prostasin includes activation of ENaC by prostasin when mammalian versions of these proteins are coexpressed in frog oocytes [6, 28, 37]. Less direct evidence includes prostasin's sensitivity to inhibitors of ENaC-mediated Na^+ current, like aprotinin [38], the finding that some epithelial cells that express ENaC also express prostasin [15], and phylogenetic evidence that prostasins are relatives of frog channel-activating protease [39].

Electrophysiological studies of airway epithelia in cystic fibrosis (CF) suggest that Na^+ uptake from the lumen is dysregulated and excessive [40–42]. The leading hypothesis regarding the cause of airways disease in CF is that excessive

FIGURE 1: Role of prostasin in airway epithelium.

Na^+ absorption leads to inadequate hydration resulting in mucus stasis and recurrent infection (Figure 1) and has prompted searches for ways to redress the postulated imbalance [14, 17]. Identification and inhibition of a proteolytic regulator of airway ENaC could provide a pharmacological means of improving Na^+ current in CF airway. However, disordered regulation of ENaC by mutated CF transmembrane regulator protein may be the direct and dominant cause of the defect in CF [43].

In a study by Tong et al. in 2004, membrane-anchored prostasin was found to be highly expressed in CF epithelial cells, and the silencing of expression strongly reduced transepithelial Na^+ current. This is direct evidence that prostasin is the major positive regulator of baseline ENaC activity in CF epithelium [44].

5. Role of Prostasin in Fluid and Electrolyte Regulation Actions at Renal Level

Epithelial sodium channel (ENaC) performs an essential function in several epithelial tissues, including the colon, kidney, and lung [7, 14, 45]. The epithelial sodium channel (ENaC) consisting of α -, β -, and γ -subunits is expressed in the renal distal tubules and constitutes the rate-limiting step for sodium reabsorption [46]. Two monogenic disorders, Liddle's syndrome (salt-retaining hypertension), and pseudohypoaldosteronism type 1 (salt-wasting hypotension) highlight the significance of genetic defects of ENaC in sodium homeostasis and blood pressure (BP) regulation [46]. Furthermore, genetic variants of α -ENaC, β -ENaC, and

γ -ENaC were found to be associated with population BP variation or the presence of essential hypertension in some populations, although not in others [47–50].

In these tissues, sodium is primarily transported across the apical membrane via ENaC, and fluid transport across the membrane is highly responsive to sodium concentration. Several disease states like hypertension and cystic fibrosis can be affected by modulation of ENaC activity. Inappropriate function of ENaC leads to dysregulation of blood pressure in humans [51]. The same ENaC mutations which lead to hypertension in humans give rise to defects in lung fluid clearance in mice [51], suggesting that proper ENaC function may also be important in other diseases where sodium and fluid homeostasis is severely disrupted, for example, cystic fibrosis [52]. ENaC dysregulation leads to dehydration of airway surfaces in patients with cystic fibrosis, which in turn disrupts the primary innate lung defense mechanism, mucus clearance. In the last few years, a novel mechanism modulating ENaC activity by serine proteases was identified. Prostasin, one of the important serine peptidases, has been shown to regulate fluid and electrolyte regulation via proteolysis of the gamma (γ) subunit of epithelial sodium channel [7, 14]. Cleavage of an inhibitory peptide in the γ -ENaC subunit by prostasin has been shown to stimulate sodium transport by 2–3-fold in cell-based experiments [7, 14]. Degree of proteolytic activation of ENaC is modulated by the balance between channel-activating protease activity and soluble protease inhibitor concentrations present on the apical surface of airway epithelium [34, 53]. A study done by Myerburg et al. [43] demonstrated that abnormal prostasin regulation in CF epithelia leads to excessive proteolytic activation of ENaC and that this plays a significant role in the Na^+ hyperabsorption characteristic of CF airway disease. Further defining of the regulation of proteolytic cascades on the airway cell surface may reveal novel targets for CF therapeutics beyond the protease inhibitors currently under trial.

Another possible role of prostasin in maintenance of fluid and electrolytes is aldosterone dependant. Prostasin seems to be involved in aldosterone-dependent ENaC activation at renal level; however, it is unclear whether aldosterone increases prostasin expression or, on the contrary, a preceding stimulation of prostasin determines adrenal secretion of aldosterone (Figure 2). In 2002, Narikiyo et al. [17] demonstrated that aldosterone substantially increases prostasin expression, with functional consequences on Na^+ balance in vivo; moreover, they reported that urinary excretion of prostasin in 3 patients with aldosterone-producing adenoma was abnormally elevated and normalized after adrenalectomy. These findings suggested urinary prostasin as a possible marker of aldosterone-dependent ENaC activation at the renal level in humans. However, in 2003, Wang et al. showed that expression of human prostasin by adenovirus-mediated gene delivery was associated with subsequent increase of aldosterone and, in turn, of blood pressure levels in rats [35]. Elevated plasma aldosterone levels were detected at 3 days after gene transfer before the development of hypertension, indicating that adrenal stimulation of mineralocorticoid production by prostasin is the primary event and not vice versa

FIGURE 2: Role of prostasin in hypertension.

[35]. Proastasin regulates aldosterone production in human adrenocortical H295R cells by a protease-independent but calcium- and protein-kinase-C- (PKC-) dependent mechanism [54].

Olivieri et al. evaluated the physiological relationship linking prostasin, aldosterone, and ENaC function and proposed the role of urinary prostasin as a candidate marker for epithelial sodium channel activation in humans [55]. For this study, young students without any significant history of disease and in apparently good health, with proven normal blood pressure and normal plasma potassium, free of any hormone- or drug-related interference, were studied before and after spironolactone. A single dose of spironolactone (100 mg) was given to induce an effective competitive inhibition of aldosterone action at mineralocorticoid receptor level and, in turn, of subsequent Na^+ transport through the ENaC. Single dose of spironolactone increased urinary Na^+/K^+ ratio and decreased urinary prostasin expression. However, these effects were not generalized but were restricted to the group of individuals in whom the renin/aldosterone axis was activated by a relatively low sodium intake. Thus, in agreement with the expected inhibition of aldosterone and ENaC function, spironolactone-dependent changes in urinary Na^+ and K^+

excretion were proportional to the hormone levels, resulting as relevant or null in subjects with high or low aldosterone, respectively. Similarly, a spironolactone-inhibited aliquot of prostatic acid phosphatase was observed only in individuals with an activated renin/aldosterone axis.

Koda et al. developed a specific radioimmunoassay (RIA) for human prostatic acid phosphatase to clarify the physiological relationship among prostatic acid phosphatase, aldosterone, and ENaC. Prostatic acid phosphatase levels in urine were determined in 26 normotensive and 121 hypertensive subjects. Aldosterone content in urine and plasma, urinary Na/K ratio, and other clinical parameters were also measured. A highly significant correlation between prostatic acid phosphatase and aldosterone concentrations in urine (correlation coefficient: 0.673, $P < 0.0001$) was observed in this study. A significant correlation was also found between urinary prostatic acid phosphatase and plasma aldosterone concentrations (correlation coefficient: 0.229, $P < 0.05$). In addition, urinary prostatic acid phosphatase excretion was inversely correlated with urinary Na/K ratio (correlation coefficient: -0.425 , $P < 0.0001$). These findings suggest that urinary prostatic acid phosphatase level is strongly correlated with urinary or plasma aldosterone level and may serve as a surrogate marker for ENaC activation in hypertensive patients [56].

The increase in the levels or function of prostatic acid phosphatase caused by functional genetic variants might amplify or result in the prostatic acid phosphatase-dependent release of an inhibitory peptide from γ -ENaC, subsequently cleaving the channel and causing an increased channel gating or open probability [14]. ENaC activation in the distal nephron augments tubular sodium reabsorption and extracellular volume expansion, which leads to BP elevation.

6. Role of Prostatic Acid Phosphatase in Epithelial Cancers

Prostatic acid phosphatase's role in cancer is unclear, but there is evidence indicating that it may be related to tumor promoter mechanisms [26] as well as tumor suppressor mechanisms [18, 19, 38]. Recently, other data has also shown that prostatic acid phosphatase is involved in proteolytic cleavage of the extracellular domain of epidermal growth factor receptor (EGFR), causing a constitutively phosphorylated receptor [41] that could potentially participate in promoting tumor growth (Figure 3).

7. Epidermal Growth Factor Receptor (EGFR) Signal Modulation

The epidermal growth factor receptor (EGFR) is the cell surface receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands [36]. It exists on the cell surface and is activated by the binding of its specific ligands. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer—although there is some evidence that preformed inactive dimers may also exist before ligand binding. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of several tyrosine (Y) residues in the C-terminal domain of EGFR occurs. This autophosphorylation

FIGURE 3: Role of prostatic acid phosphatase in cancers.

elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the mitogen activated protein kinase (MAPK), Akt, and JNK pathways, leading to DNA synthesis and cell proliferation [39]. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. Mutations, amplifications, or misregulations of EGFR or family members are implicated in various epithelial cancers. Mutations involving EGFR could lead to its constant activation which could result in uncontrolled cell division—a predisposition for cancer.

Extracellular proteases and protease inhibitors are believed to play an important role during carcinogenesis in many different ways, such as degrading the extracellular matrix in order to facilitate invasive growth and activating signal molecules. In accordance with this, proteases were mostly thought of as promoters of metastasis. However, clinical trials where cancer patients were treated with broad range protease inhibitors have shown that proteases can act as tumor suppressors [40]. Prostatic acid phosphatase, a relatively new protease, is found to be involved in the extracellular proteolytic

FIGURE 4: Regulation of prostasin expression in carcinomas.

modulation of the epidermal growth factor receptor (EGFR) and is thus an invasion suppressor. Prostasin, which is found to be expressed abundantly in normal epithelia and essential for terminal epithelial differentiation [15], has been seen to be downregulated in human prostate, breast, and gastric cancers and invasive cancer cell lines (Figures 3 and 4). Fu et al. [37] investigated the impact of prostasin expression regulation on this cellular function as well as the molecular mechanisms involved in human cytotrophoblastic cells. The results of this study showed that prostasin may regulate trophoblast cell proliferation via modulating the EGFR-MAPK signaling pathway.

Recent advances in bladder cancer research have identified the process of epithelial-mesenchymal transition (EMT) as an important factor in determining disease prognosis and patient responses to therapy. EMT is known to be the main cause in the development of invasive and metastatic cancers including transitional cell carcinoma (TCC). At the molecular level, the epidermal growth factor receptor (EGFR), the cell adhesion molecule E-cadherin, and transcription repressors of E-cadherin, such as SNAIL and SLUG, have been shown to play essential and major roles in EMT and development of invasive and metastatic bladder cancer [57]. A lot of work has been carried out by Chen et al. who demonstrated that a glycosylphosphatidylinositol- (GPI-) anchored epithelial extracellular membrane serine protease, prostasin/PRSS8, modulates EGFR signalling via enhancement of matriptase cleavage of the EGFR extracellular domain (ECD) and regulates SLUG and E-cadherin expression in cancer cells [41, 42]. In their other study, the authors have showed [58] that loss of

prostasin expression in bladder transitional cell carcinomas is associated with epithelial-mesenchymal transition (EMT) and may have functional implications in tumor invasion and resistance to chemotherapy [58]. Downregulation of prostasin protein expression has also been shown to be associated with high-grade and hormone-refractory prostate cancers [19, 38], breast cancers [59], and gastric cancers [60]. Prostasin promoter DNA hypermethylation has been shown to be an epigenetic mechanism of prostasin silencing in various cancer cell lines [18, 22, 60]. Invasive human cancer cell lines are often associated with loss of prostasin expression, while prostasin reexpression inhibits their invasion through Matrigel [18, 19].

In a study by Takahashi et al., expression levels of both prostasin mRNA and protein were found to be inversely correlated with histological differentiation but not associated with clinical stage of human prostate cancer. Almost all cases of metastatic and hormone-refractory cancers demonstrated down-regulation of prostasin expression, indicating that prostasin may not be regarded as a prognostic marker for prostate cancer but a useful marker for tumor differentiation [38]. Chen et al. in 2001 showed that both prostasin protein and mRNA were expressed in normal human prostate epithelial cells and noninvasive human prostate cancer cell line, the LNCaP, but neither was found in invasive human prostate cancer cell lines DU-145 and PC-3. Prostasin mRNA expression was absent in invasive prostate cancer cell lines of a transgenic mouse model. Immunohistochemistry analysis also showed that prostasin protein expression is down-regulated in high-grade prostate cancer [19].

In experimental studies on breast cancer cell lines by Chen and Chai [18], it has been shown that prostasin mRNA and protein were expressed in normal human mammary epithelial cells (NHMEC), the poorly invasive breast carcinoma cell line MCF-7, and the nonmetastatic breast carcinoma cell line MDA-MB-453, but absent in highly invasive and metastatic breast carcinoma cell lines MDA-MB-231 and MDA-MB-435s. Enforced reexpression of prostasin in MDA-MB-231 and MDA-MB-435s reduced the in vitro invasiveness of either cell line by 50%. Examination of the prostasin gene promoter and first exon revealed a GC-enriched region that contains transcription regulatory elements. The promoter and exon 1 region of the prostasin gene was investigated for DNA methylation in NHMEC and the carcinoma cell lines. The results revealed a methylation pattern that correlates with prostasin expression in these cells. Demethylation coupled with histone deacetylase inhibition resulted in reactivated expression of the prostasin mRNA in MDA-MB-231 and MDA-MB-435s cells. These results suggest that prostasin expression in breast cancer cells may be regulated by DNA methylation and that an absence of prostasin expression may contribute to breast cancer invasiveness and metastatic potential. In another study by Bergum et al. in 2012, a coordinated coexpression pattern has been reported for prostasin and its activating enzyme/substrate matriptase in human breast cancers [61]. Furthermore, matriptase and prostasin displayed a near identical spatial expression pattern in the epithelial compartment of breast cancer tissue [61].

Selzer-Plon et al. investigated the mRNA levels of prostasin and its inhibitors PN-1, HAI-1A, and HAI-1B, during colorectal cancer carcinogenesis in humans. Their data demonstrated that elevated mRNA levels for prostasin inhibitor, PN-1, coincides with the acquisition of malignant properties, whereas the mRNA level of prostasin is relatively stable during colorectal cancer carcinogenesis [62]. It shows that the action of proteases may be regulated not necessarily by the expression of the protease but by regulating the expression of its inhibitors. It could thus be speculated that the transition from severe dysplasia to cancer is accompanied by a transcriptional decrease in prostasin expression and/or a downregulation of prostasin activity via upregulation of one or more enzymatic inhibitors of prostasin. In a study by Cavalieri et al., prostasin mRNA expression was found to be correlated to prolonged survival after surgery in colon cancer patients [63].

Unlike bladder and colon cancer, an upregulation of prostasin has been reported in ovarian carcinoma [64, 65]. The potential use of prostasin as a marker of ovarian cancer has been suggested in a study by Mok et al. [64] that demonstrated 120- to 410-fold higher prostasin mRNA expression in ovarian cancer cell lines than normal ovarian cell lines. The abnormal expression of prostasin in these cell lines was further confirmed at the protein level by immunostaining. They found higher levels of serum prostasin in case patients with ovarian cancer than in control subjects and declining levels of prostasin after surgery for ovarian cancer [64]. The poor prognosis associated with ovarian cancer is mainly due to the fact that the majority of patients are diagnosed in the advanced stages of the disease.

8. Conclusion

Prostasin, a serine protease capable of regulating epithelial sodium channel, seems to have a vast potential as a biomarker in cystic fibrosis and hypertension. Further studies and research in this area will highlight the potential role of prostasin as a screening marker for cancers or a therapeutic agent for treating invasive and chemoresistant tumors.

References

- [1] J. X. Yu, L. Chao, and J. Chao, "Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland," *Journal of Biological Chemistry*, vol. 269, no. 29, pp. 18843–18848, 1994.
- [2] J. X. Yu, L. Chao, and J. Chao, "Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA," *Journal of Biological Chemistry*, vol. 270, no. 22, pp. 13483–13489, 1995.
- [3] A. Shipway, H. Danahay, J. A. Williams, D. C. Tully, B. J. Backes, and J. L. Harris, "Biochemical characterization of prostasin, a channel activating protease," *Biochemical and Biophysical Research Communications*, vol. 324, no. 2, pp. 953–963, 2004.
- [4] G. M. Verghese, M. F. Gutknecht, and G. H. Caughey, "Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor," *American Journal of Physiology*, vol. 291, no. 6, pp. C1258–C1270, 2006.
- [5] L.-M. Chen, M. L. Skinner, S. W. Kauffman et al., "Prostasin is a glycosylphosphatidylinositol-anchored active serine protease," *Journal of Biological Chemistry*, vol. 276, no. 24, pp. 21434–21442, 2001.
- [6] S. H. Donaldson, A. Hirsh, D. C. Li et al., "Regulation of the epithelial sodium channel by serine proteases in human airways," *Journal of Biological Chemistry*, vol. 277, no. 10, pp. 8338–8345, 2002.
- [7] G. Vuagniaux, V. Vallet, N. F. Jaeger et al., "Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAPP expressed in a mouse cortical collecting duct cell line," *Journal of the American Society of Nephrology*, vol. 11, no. 5, pp. 828–834, 2000.
- [8] G. H. Caughey, W. W. Raymond, J. L. Blount et al., "Characterization of human γ -tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families," *Journal of Immunology*, vol. 164, no. 12, pp. 6566–6575, 2000.
- [9] S. Netzel-Arnett, J. D. Hooper, R. Szabo et al., "Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer," *Cancer and Metastasis Reviews*, vol. 22, no. 2-3, pp. 237–258, 2003.
- [10] F. P. Costa, E. L. Batista Jr., A. Zelmanowicz et al., "Prostasin, a potential tumor marker in ovarian cancer—A Pilot Study," *Clinics*, vol. 64, no. 7, pp. 641–644, 2009.
- [11] S. C. Mok, J. Chao, S. Skates et al., "Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology," *Journal of the National Cancer Institute*, vol. 93, no. 19, pp. 1458–1464, 2001.
- [12] V. Vallet, A. Chraïbi, H.-P. Gaeggeler, J.-D. Horisberger, and B. C. Rossier, "An epithelial serine protease activates the amiloride-sensitive sodium channel," *Nature*, vol. 389, no. 6651, pp. 607–610, 1997.

- [13] V. Vallet, C. Pfister, J. Loffing, and B. C. Rossier, "Cell-surface expression of the channel activating protease xCAP-1 is required for activation of ENaC in the *Xenopus* oocyte," *Journal of the American Society of Nephrology*, vol. 13, no. 3, pp. 588–594, 2002.
- [14] J. B. Bruns, M. D. Carattino, S. Sheng et al., "Epithelial Na⁺ channels are fully activated by furin- and prostaticin-dependent release of an inhibitory peptide from the γ -subunit," *Journal of Biological Chemistry*, vol. 282, no. 9, pp. 6153–6160, 2007.
- [15] C. Leyvraz, R. P. Charles, I. Rubera et al., "The epidermal barrier function is dependent on the serine protease CAP1/Prss8," *Journal of Cell Biology*, vol. 170, no. 3, pp. 487–496, 2005.
- [16] L.-M. Chen, C. Wang, M. Chen et al., "Prostaticin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation," *American Journal of Physiology*, vol. 291, no. 3, pp. F567–F577, 2006.
- [17] T. Narikiyo, K. Kitamura, M. Adachi et al., "Regulation of prostaticin by aldosterone in the kidney," *Journal of Clinical Investigation*, vol. 109, no. 3, pp. 401–408, 2002.
- [18] L.-M. Chen and K. X. Chai, "Prostaticin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter dna methylation," *International Journal of Cancer*, vol. 97, no. 3, pp. 323–329, 2002.
- [19] L.-M. Chen, G. Byron Hodge, L. A. Guarda, J. L. Welch, N. M. Greenberg, and K. X. Chai, "Down-regulation of prostaticin serine protease: a potential invasion suppressor in prostate cancer," *Prostate*, vol. 48, no. 2, pp. 93–103, 2001.
- [20] K. W. Rickert, P. Kelley, N. J. Byrne et al., "Structure of human prostaticin, a target for the regulation of hypertension," *Journal of Biological Chemistry*, vol. 283, no. 50, pp. 34864–34872, 2008.
- [21] J.-D. Vassalli, J. Huarte, D. Bosco et al., "Protease-nexin I as an androgen-dependent secretory product of the murine seminal vesicle," *EMBO Journal*, vol. 12, no. 5, pp. 1871–1878, 1993.
- [22] L.-M. Chen, X. Zhang, and K. X. Chai, "Regulation of prostaticin expression and function in the prostate," *Prostate*, vol. 59, no. 1, pp. 1–12, 2004.
- [23] D. J. Knauer, J. A. Thompson, and D. D. Cunningham, "Protease nexins: cell-secreted proteins that mediate the binding, internalization, and degradation of regulatory serine proteases," *Journal of Cellular Physiology*, vol. 117, no. 3, pp. 385–396, 1983.
- [24] B. Fan, T. D. Wu, W. Li, and D. Kirchhofer, "Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostaticin," *Journal of Biological Chemistry*, vol. 280, no. 41, pp. 34513–34520, 2005.
- [25] Y.-W. Chen, J.-K. Wang, F.-P. Chou et al., "Regulation of the matriptase-prostaticin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation," *Journal of Biological Chemistry*, vol. 285, no. 41, pp. 31755–31762, 2010.
- [26] A. Maekawa, Y. Kakizoe, T. Miyoshi et al., "Camostat mesilate inhibits prostaticin activity and reduces blood pressure and renal injury in salt-sensitive hypertension," *Journal of Hypertension*, vol. 27, no. 1, pp. 181–189, 2009.
- [27] K. Coote, H. C. Atherton-Watson, R. Sugar et al., "Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease," *Journal of Pharmacology and Experimental Therapeutics*, vol. 329, no. 2, pp. 764–774, 2009.
- [28] D. Kirchhofer, M. Peek, W. Li et al., "Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1," *Journal of Biological Chemistry*, vol. 278, no. 38, pp. 36341–36349, 2003.
- [29] S. Netzel-Arnett, B. M. Currie, R. Szabo et al., "Evidence for a matriptase-prostaticin proteolytic cascade regulating terminal epidermal differentiation," *Journal of Biological Chemistry*, vol. 281, no. 44, pp. 32941–32945, 2006.
- [30] M. D. Oberst, L.-Y. L. Chen, K.-I. Kiyomiya et al., "HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease," *American Journal of Physiology*, vol. 289, no. 2, pp. C462–C470, 2005.
- [31] M. D. Oberst, C. A. Williams, R. B. Dickson, M. D. Johnson, and C.-Y. Lin, "The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor," *Journal of Biological Chemistry*, vol. 278, no. 29, pp. 26773–26779, 2003.
- [32] K. List, R. Szabo, P. W. Wertz et al., "Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1," *Journal of Cell Biology*, vol. 163, no. 4, pp. 901–910, 2003.
- [33] K. List, C. C. Haudenschild, R. Szabo et al., "Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis," *Oncogene*, vol. 21, no. 23, pp. 3765–3779, 2002.
- [34] R. Tarran, L. Trout, S. H. Donaldson, and R. C. Boucher, "Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia," *Journal of General Physiology*, vol. 127, no. 5, pp. 591–604, 2006.
- [35] C. Wang, J. Chao, and L. Chao, "Adenovirus-mediated human prostaticin gene delivery is linked to increased aldosterone production and hypertension in rats," *American Journal of Physiology*, vol. 284, no. 4, pp. R1031–R1036, 2003.
- [36] R. S. Herbst, "Review of epidermal growth factor receptor biology," *International Journal of Radiation Oncology Biology Physics*, vol. 59, supplement 2, pp. 21–26, 2004.
- [37] Y.-Y. Fu, W.-L. Gao, M. Chen, K. X. Chai, Y.-L. Wang, and L.-M. Chen, "Prostaticin regulates human placental trophoblast cell proliferation via the epidermal growth factor receptor signaling pathway," *Human Reproduction*, vol. 25, no. 3, pp. 623–632, 2010.
- [38] S. Takahashi, S. Suzuki, S. Inaguma et al., "Down-regulated expression of prostaticin in high-grade or hormone-refractory human prostate cancers," *Prostate*, vol. 54, no. 3, pp. 187–193, 2003.
- [39] D. Tvorogov and G. Carpenter, "EGF-dependent association of phospholipase C- γ 1 with c-Cbl," *Experimental Cell Research*, vol. 277, no. 1, pp. 86–94, 2002.
- [40] C. López-Otín and L. M. Matrisian, "Emerging roles of proteases in tumour suppression," *Nature Reviews Cancer*, vol. 7, no. 10, pp. 800–808, 2007.
- [41] M. Chen, L.-M. Chen, C.-Y. Lin, and K. X. Chai, "The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostaticin serine protease cascade in cultured epithelial cells," *Biochimica et Biophysica Acta*, vol. 1783, no. 5, pp. 896–903, 2008.
- [42] M. Chen, Y.-Y. Fu, C.-Y. Lin, L.-M. Chen, and K. X. Chai, "Prostaticin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3," *Biochimica et Biophysica Acta*, vol. 1773, no. 7, pp. 1133–1140, 2007.
- [43] M. M. Myerburg, E. E. McKenna, C. J. Luke, R. A. Frizzell, T. R. Kleyman, and J. M. Pilewski, "Prostaticin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis," *American Journal of Physiology*, vol. 294, no. 5, pp. L932–L941, 2008.

- [44] Z. Tong, B. Illek, V. J. Bhagwandin, G. M. Verghese, and G. H. Caughey, "Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line," *American Journal of Physiology*, vol. 287, no. 5, pp. L928–L935, 2004.
- [45] M. Adachi, K. Kitamura, T. Miyoshi et al., "Activation of epithelial sodium channels by prostasin in *Xenopus* oocytes," *Journal of the American Society of Nephrology*, vol. 12, no. 6, pp. 1114–1121, 2001.
- [46] K. Gormley, Y. Dong, and G. A. Sagnella, "Regulation of the epithelial sodium channel by accessory proteins," *Biochemical Journal*, vol. 371, no. 1, pp. 1–14, 2003.
- [47] A. Persu, P. Barbry, F. Bassilana et al., "Genetic analysis of the β subunit of the epithelial Na^+ channel in essential hypertension," *Hypertension*, vol. 32, no. 1, pp. 129–137, 1998.
- [48] A. Persu, S. Coscoy, A.-M. Houot, P. Corvol, P. Barbry, and X. Jeunemaitre, "Polymorphisms of the γ subunit of the epithelial Na^+ channel in essential hypertension," *Journal of Hypertension*, vol. 17, no. 5, pp. 639–645, 1999.
- [49] W. T. Ambrosius, L. J. Bloem, L. Zhou et al., "Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension," *Hypertension*, vol. 34, no. 4 I, pp. 631–637, 1999.
- [50] J. M. Hollier, D. F. Martin, D. M. Bell et al., "Epithelial sodium channel allele T594M is not associated with blood pressure or blood pressure response to amiloride," *Hypertension*, vol. 47, no. 3, pp. 428–433, 2006.
- [51] H. Garty and L. G. Palmer, "Epithelial sodium channels: function, structure and regulation," *Physiological Reviews*, vol. 77, no. 2, pp. 359–396, 1997.
- [52] S. H. Donaldson and R. C. Boucher, "Sodium channels and cystic fibrosis," *Chest*, vol. 132, no. 5, pp. 1631–1636, 2007.
- [53] M. M. Myerburg, M. B. Butterworth, E. E. McKenna et al., "Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis," *Journal of Biological Chemistry*, vol. 281, no. 38, pp. 27942–27949, 2006.
- [54] T. Ko, Y. Kakizoe, N. Wakida et al., "Regulation of adrenal aldosterone production by serine protease prostasin," *Journal of Biomedicine and Biotechnology*, vol. 2010, Article ID 793843, 9 pages, 2010.
- [55] O. Olivieri, A. Castagna, P. Guarini et al., "Urinary prostasin: a candidate marker of epithelial sodium channel activation in humans," *Hypertension*, vol. 46, no. 4, pp. 683–688, 2005.
- [56] A. Koda, N. Wakida, K. Toriyama et al., "Urinary prostasin in humans: relationships among prostasin, aldosterone and epithelial sodium channel activity," *Hypertension Research*, vol. 32, no. 4, pp. 276–281, 2009.
- [57] S. Barr, S. Thomson, E. Buck et al., "Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions," *Clinical and Experimental Metastasis*, vol. 25, no. 6, pp. 685–693, 2008.
- [58] L.-M. Chen, N. J. Verity, and K. X. Chai, "Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT)," *BMC Cancer*, vol. 9, article 377, 2009.
- [59] C. Jones, A. Mackay, A. Grigoriadis et al., "Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of Novel Prognostic Markers for breast cancer," *Cancer Research*, vol. 64, no. 9, pp. 3037–3045, 2004.
- [60] K. Sakashita, K. Mimori, F. Tanaka et al., "Clinical significance of low expression of Prostasin mRNA in human gastric cancer," *Journal of Surgical Oncology*, vol. 98, no. 7, pp. 559–564, 2008.
- [61] C. Bergum, G. Zoratti, J. Boerner, and K. List, "Strong expression association between matriptase and its substrate prostasin in breast cancer," *Journal of Cellular Physiology*, vol. 227, no. 4, pp. 1604–1609, 2012.
- [62] J. Selzer-Plon, J. Bornholdt, S. Friis et al., "Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis," *BMC Cancer*, vol. 9, article 201, 2009.
- [63] D. Cavalieri, P. Dolara, E. Mini et al., "Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer," *Oncology Research*, vol. 16, no. 11, pp. 535–548, 2007.
- [64] S. C. Mok, J. Chao, S. Skates et al., "Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology," *Journal of the National Cancer Institute*, vol. 93, no. 19, pp. 1458–1464, 2001.
- [65] F. P. Costa, E. L. Batista Jr., A. Zelmanowicz et al., "Prostasin, a potential tumor marker in ovarian cancer—A Pilot Study," *Clinics*, vol. 64, no. 7, pp. 641–644, 2009.